Summary The therapeautic efficacy of intact and F(ab')2 fragments of a "'I anti-CEA antibody were compared in an established LS174T colonic xenograft model in nude mice. A single IV dose of either 0.5 mCi (18.5 MBq) intact or 1.0 mCi (37 MBq) F(ab')2 fragments significantly delayed tumour growth, and increased survival time to the same extent. Biodistribution studies showed that the more rapid clearance of the fragments from the circulation improved the tumour:normal tissue ratios found for the intact antibody, but reduced the duration and therefore absolute amount of radioantibody localisation (% injected dose/gram) at the tumour site. The tumours received a similar accumulated beta radiation dose, with 4,065 cGy from 0.5 mCi intact antibody and 4,500 cGy from 1.0 mCi F(ab')2 fragments. The dose rate to the tumour was initially higher for the fragments, but fell off more rapidly as clearance occurred. However, the rapid circulatory clearance resulted in a radiation dose of only 995 cGy to the blood, compared with 2,300 cGy for the intact antibody. This suggests that twice the radiation dose could be delivered to the tumour in the form of fragments for the same blood dose from the intact antibody. Fractionating the 1.0 mCi dose of F(ab')2 into three doses of 0.33 mCi (12.2 MBq), given on days 1, 3 and 5, significantly reduced the therapeutic effect of the treatment. The clinical relevance of these findings is discussed.
The successful tumour localisation of radiolabelled antibodies raised against carcinoembryonic antigen (CEA), a tumour associated marker of epithelial carcinomas, has led to the investigation of radioimmunotherapy as a form of cancer treatment in both animal xenograft models (Buchegger et al., 1988; Sharkey et al., 1987; Pedley et al., 1991) and in man (Begent et al., 1989; DeNardo et al., 1988) . Antibodies labelled with isotopes emitting medium-to high-energy beta particules such as 13'I and 90Y are promising for solid tumour therapy, because they can deposit their energy over a range of more than 40 cells without requiring either binding to each individual cell or internalisation.
However, a major drawback to the use of radioimmunotherapy is the potential damage to normal tissues from the high doses due to circulating radioantibody. The more rapid circulatory clearance and increased tumour penetration normally produced by antibody fragments make them an attractive alternative to intact antibody for tumour localisation and therapy, although they do have the disadvantage of also clearing more rapidly from the tumour itself.
We have previously reported on the comparative tumour localisation and clearance patterns of intact IgG and antibody fragments in the nude mouse model (Harwood et al., 1985) . The present study compares the therapeutic efficacy of a radiolabelled intact antibody and its F(ab')2 fragments. We have compared the effect of a single dose of "3'I-Fab(ab')2 A5B7, an anti-CEA antibody, with that of the intact antibody on the colonic tumour xenograft LS174T grown in nude (nu/nu) mice, and have related this to the respective biodistribution and clearance patterns of the antibodies. The effect produced on radioimmunotherapy by fractionating the single dose of F(ab')2 A5B7 has also been examined.
A dosimetric study, based on biodistribution and clearance, has been carried out in order to compare the observed therapeautic effect obtained for intact antibody and fragments with the total radiation dose received by the tumour and blood in each case. In order to demonstrate how this accumulated total radiation dose was delivered over time, dose rates to the tumour and blood from both the intact A5B7 and the F(ab')2 fragments were also calculated for selected time points after radioantibody administration.
Materials and methods

Antibodies
Radiolabelling Both intact and F(ab')2 fragments of A5B7, a monoclonal anti-CEA antibody (Pedley et al., 1987) , were labelled with "3iodine by the chloramine T method to a specific activity of approx. 10 mCi mg-' protein, and passed through a 0.22mm Gelman filter (Northampton, UK). F(ab')2 fragments These were prepared from a concentrated solution of A5B7 (20 mg ml-') by pepsin (Sigma) digestion in a 0.1 M sodium acetate solution, pH 4.5. Incubation was for 16-18 h at 37°C, and the reaction was terminated by dialysis in PBS at pH 7.5. Antibody purification was carried out by affinity chromatography using Protein A-sepharose (Pharmacia), eluted with citrate buffer pH 3, followed by gel filtration on Sephacryl S-200 (Pharmacia) to separate the F(ab')2 fragments. Purity was checked by SDS-PAGE. The intact ASB7 and the F(ab')2 fragments are in regular clinic use for both localisation and therapy studies.
Animal studies
Xenografts A human colon adenocarcinoma cell line LS174T (Tom et al., 1976) was used to develop a xenograft tumour model in the flank of female nude (nu/nu) mice by subcutaneous cell inoculation. Subsequent passaging was by continuous subcutaneous implantation from the original xenograft. All mice used were 2-3 months old, with a weight of between 20-25 g. The tumour is a moderately differentiated CEA-producing adenocarcinoma with small glandular acini, which secretes no measurable CEA into the circulation. ASB7 gives positive staining for the glandular luminal surface and cytoplasm in the LS174T xenograft, and there is also some reactivity with necrotic debris and glandular contents.
Radioimmunotherapy studies The experiments proceeded when the tumours were between 0.1-0.2 cm3 in volume and in exponential growth (10-14 days after passaging), using 6 mice per group. All antibody administration was via the tail vein. For single dose therapy the mice were given either 0.5 mCi of intact antibody or 1.0 mCi of F(ab')2 fragments, calculated from previous preliminary distribution studies (not shown) by the trapezoidal rule to give the same total radiation dose to the blood (Jeffrey, 1985) . Fractionated (Lee & Desu, 1972) . 'Significant' indicates a P value of below 0.05.
Dosimetry
This was calculated as previously described (Pedley et al., 1989) . In brief, for each biodistribution time point of A5B7 and F(ab')2 A5B7 the counts per gram for blood and tumour were re-normalised in terms of injected activity. Clearance curves were then constructed from the percentage activity remaining, displaying the combined effects of both radionuclide decay and organ clearance. By relating each initial value of counts per gram to the injected activity, the percentage of initial administered activity (PIA) was obtained for each organ. For each of the antibodies used, the fractional beta dose delivered to each tissue during successive elements of the clearance curve were computed using a standard equation for dosimetry in tissue (MIRD Pamphlet No. 11, 1975) . The total beta dose to 144 h (DP) was then obtained by summation of all these fractional dose elements. Using the derived values of PIA and DP, the individual tissue doses were calculated for the antibodies.
Dose rates (cGy h -) delivered at the tumour site and to blood by both the intact and F(ab')2 A5B7 at selected time points after radioantibody administration were also determined using the same MIRD calculations.
Results
The data presented are representative of a series of experiments giving similar results.
Single dose radioimmunotherapy Figure 1 shows the mean tumour growth following either 0.5 mCi intact '13I A5B7 or 1.0 mCi F(ab')2 fragments. Both these treatments produced a significant therapeutic effect when compared with the group receiving no treatment ( Figure 1 ). Tumour growth was inhibited for 28 days in the case of intact A5B7, and for 26 days in the case of fragments. When the two therapy groups were compared, there was no significant difference between the prolonged survival effects produced by each treatment. Administration of unlabelled intact antibody or F(ab')2 fragments had no effect on tumour growth or animal survival time (not shown). Multiple dose radiotherapy Figure 2 shows the effect on therapy of fractionating the single 1.0 mCi dose of F(ab')2 A5B7 in three doses of 0.33 mCi each, given on days 1, 3 and 5. Both treatment groups again showed significant inhibition of tumour growth and prolongation of survival when compared with the group receiving no treatment ( Figure 2 A5B7. The dose rates delivered to tumour and blood at selected times after administration of either 0.5 mCi intact or 1.0 mCi F(ab')2 A5B7 are shown in Table II . At 6 h the two treatments were giving a similar radiation dose to the blood, but by 24 h the dose rate from the '3"I-F(ab')2 was already reduced to a third of the intact rate, the latter remaining high throughout the experiment. The dose rate to tumour from the fragments was initially higher than that produced by the intact antibody (40 cGyh-' compared with 26.6 cGyh-' at 6h), but fell off rapidly with time. That from the intact antibody peaked at 24 h (38.4 cGy h-'), followed by a more gradual decline in dose rate over the 6 days. These activity patterns reflect the antibody biodistribution and clearance shown in Figure 3 .
Dosimetry
Discussion
We have previously shown that a single 0.5 mCi intravenous injection of either "3'I-labelled monoclonal (A5B7) or polyclonal (PK4S) anti-CEA antibody significantly inhibited the growth of a well established colonic xenograft in nude mice, and caused temporary tumour regression. Radiolabelled nonspecific antibody delayed tumour growth for a few days only, with no significant increase in survival time, while unlabelled specific antibody had no effect on tumour growth (Pedley et al., 1991) .
The present results demonstrate that twice the activity of radioantibody must be administered as F(ab')2 fragments in order to produce the same therapeutic effect as the intact antibody (Figure 1 ). This is because the more rapid circulatory clearance of fragments via the kidney during the initial few hours after administration (Figure 3 ) results in a lower absolute amount to the tumour when compared with suggesting that the tumour dose may be an underestimate. In agreement with the present work, he also found that the fragments were less toxic than the intact antibody although they were administered in larger amounts. Dosimetry calculations, based on a more detailed study of early biodistribution of F(ab')2 A5B7 in the LS174T model, suggest that a total 1B radiation dose of 995 cGy was delivered to the blood, while the tumour received 4,500 cGy, for each mCi administered (Table I ). The equivalent figures for the 0.5 mCi dose of intact antibody were 2,300 cGy to the blood and 4,065 cGy to the tumour. These calculated tumour doses are borne out by their similar therapeutic effects, shown in Figure 1 . The reduction in dose to the blood from fragment administration indicates that four times the dose of intact antibody (i.e. 2 mCi) could safely be administered in the form of F(ab')2 fragments, which should double the therapeutic effect produced in the present experiments. These dosimetry results are in close agreement with those of Buchegger et al. (1989) , who calculated that a single 2.2 mCi injection of anti-CEA F(ab')2 fragments in a colonic xenograft model delivered 8,335 cGy to the tumour and 2,093 cGy to the blood. This produced complete remission in all of the mice treated, although some bone marrow transplantation was required. We have already achieved an inhibition of tumour regrowth for 26 days after a single dose of 1 mCi F(ab')2 fragments, and therefore we are now carrying out dose escalation studies which should significantly improve this.
The higher cumulative radiation dose to the tumour produced by the intact monoclonal '311-A5B7 when compared with the polyclonal "311-PK4S (Table I ) is in agreement with both the superior tumour localisation and therapeutic effect found for the monoclonal antibody in previous experiments (Pedley et al., 1991) .
Fractionating the same dose of F(ab')2 fragments significantly reduced the therapeutic effect of the treatment when compared to administration as a single dose (Figure 2 ). Some authors suggest that fractionation is at least as effective as the administration of a single high dose of radioantibody and may be less toxic to the host (Buchegger et al., 1989; Schlom et al., 1990 ), but -this can depend on a variety of factors including the number and timing of doses, tumour doubling time and the size of the initial dose. We found that the tumour to blood ratio produced by the three fractionated doses at 144 h was inferior to that resulting from the single I mCi dose (3.0:1 cp 8.4:1), so alternative timing regimes for antibody administration will be investigated. We will also be looking at fractionation as a way of delivering higher doses of fragments which would be toxic if delivered in a single administration. Dose fractionation may be of greater importance in radioimmunotherapy using intact antibody, where toxicity is a more serious problem, but repeated antibody delivery will increase the development of HAMA responses in patients.
The timing of maximum activity delivery to the tumour at the time points studied differed for the intact and F(ab')2 fragments, and was consistent with the more rapid equilibration between plasma and extracellular fluid for the F(ab')2 than for the intact antibody (Table II) . The earlier peak and more rapid clearance in tumour localisation found for the F(ab')2 gave maximum dose rate at 6 h after antibody administration, while the slower localisation but prolonged tumour retention of the intact antibody gave a peak rate at 24 h with prolonged delivery over 6 days. The tumour appears to require a high initial dose of radiation in order to kill enough cells for effective therapy. As the dose rate of beta radiation is lowered its effectiveness is also reduced, because tumour growth rate can exceed the cell kill rate and also more time is available for repair of the sublethal damage while the dose is still being delivered (Fowler, 1990 (Table II) . The rapid circulatory clearance of the fragments significantly reduced the time during which the bone marrow was subjected to a high radiation dose when compared to the intact antibody. By 24 h the dose rate to blood for the intact antibody was 27.2 cGy h', while that for the F(ab')2 had already fallen to 8.7cGyh1'.
Much of the published work may underestimate the value of radioimmunotherapy. Despite the theoretical inadequacy of radiation doses achieved to the tumour when compared to external beam radiotherapy, responses have been seen in both animals and patients (Cheung et al., 1986; Sharkey et al., 1987 , Begent et al., 1989 . Low-dose-rate intracavity and interstitial radioactive implants give figures of about 50 cGy h'-, while the dose rate from radioimmunotherapy is generally around 10-20 cGy h- (Fowler, 1990 ). This would not, therefore, be considered sufficient for a significant therapeutic effect to be observed, particularly if the tumour combines a short doubling time with a low intrinsic radiosensitivity (Dale, 1989) . In the present situation, however, with good antibody localisation in the tumour, double this dose rate is delivered by both intact antibody and F(ab')2 fragments for at least the first day or two after administration (Table II) , and so the observed therapy results are in agreement with these figures. Radioimmunotherapy also has the advantage of the dose being delivered over a few days rather than weeks, especially in the case of rapidly proliferating tumours, while the heterogeneous microdistribution of the antibody may give selectively higher than estimated doses to the viable areas of the tumour (Humm & Cobb, 1990 ). Results in patients should be improved if smaller tumours are treated, because radioantibody uptake is inversely related to tumour size (Pedley et al., 1987) . The present increase in therapeutic ratio found for F(ab')2 fragments, and the subsequent possibility of employing higher doses of radioantibody in this form without increasing the radiation damage to bone marrow, should therefore be of relevance in improving future patient treatment, with or without adjuvant therapy. It must be borne in mind that the circulatory clearance of radioantibody can differ between mice and man, and that the latter will receive a higher gamma dose to the whole body with lower bone marrow tolerance to radiation (Buchegger et al., 1989; Begent & Pedley, 1990) . However, the good correlation we have achieved between observed therapeutic results and calculated radiation doses delivered to the tumour confirms the suitability of this model for the assessment of future radioimmunotherapy modalities prior to clinical trials.
